Similar Papers

Paper Title
Journal
Date
Author
Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
Bin Zhang ... Ravi Bhatia
Cancer Cell | VOL. 17
Bin Zhang, et. al.Bin Zhang ... Ravi Bhatia
01 May 2010
Long‐term experience with imatinib therapy in chronic phase chronic myelogenous leukemia—Remarkable activity with room for improvement
Ayalew Tefferi ... Hagop Kantarjian
American Journal of Hematology | VOL. 83
Ayalew Tefferi, et. al.Ayalew Tefferi ... Hagop Kantarjian
07 Jan 2008
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
David L Porter ... Koen Van Besien
Biology of Blood and Marrow Transplantation | VOL. 16
David L Porter, et. al.David L Porter ... Koen Van Besien
08 Aug 2010
Clinical and laboratory features of leukemias at the time of diagnosis: An analysis of 1,004 consecutive patients
Zdenek Racil ... Martina Toskova
American Journal of Hematology | VOL. 86
Zdenek Racil, et. al.Zdenek Racil ... Martina Toskova
02 Aug 2011
View more papers

More From: Precision Medicine Communications

Paper Title
Journal
Date
Author
Pharmacogenomics of Sorafenib in Liver Cancer
Sagheer Ahmed
Precision Medicine Communications | VOL. 4
Sagheer AhmedSagheer Ahmed
31 Dec 2025
Genetic Determinants of Azathioprine Efficacy
Sagheer Ahmed
Precision Medicine Communications | VOL. 4
Sagheer AhmedSagheer Ahmed
31 Dec 2025
ASSOCIATION OF CYP2D6 GENE POLYMORPHISMWITH FLUOXETINE INDUCED ADVERSE REACTIONSIN PATIENTS WITH MAJOR DEPRESSION
Inzemam Haq
Precision Medicine Communications | VOL. 4
Inzemam HaqInzemam Haq
31 Dec 2025
Role of personalized medicine in silico
Fawad Bangash
Precision Medicine Communications | VOL. 4
Fawad BangashFawad Bangash
31 Dec 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.